Clinical Research Directory
Browse clinical research sites, groups, and studies.
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Sponsor: Arsenal Biosciences, Inc.
Summary
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Official title: An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
190
Start Date
2026-01-09
Completion Date
2031-05
Last Updated
2026-03-31
Healthy Volunteers
No
Interventions
AB-3028
autologous T cell therapy
Locations (4)
City of Hope
Duarte, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of Iowa and Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
Perlmutter Cancer Center - NYU Langone Health
New York, New York, United States